Atossa Therapeutics Raises $16.5 Million with New Direct Offering to Enhance Oncology Research

Atossa Therapeutics Secures $16.5 Million Direct Offering

Atossa Therapeutics, Inc. (Nasdaq: ATOS) has announced a new registered direct offering aimed at securing up to $16.5 million in gross proceeds. This strategic financial move is designed to bolster the company's clinical development efforts and advance its portfolio of oncology therapies.

On June 11, 2026, Atossa revealed that it entered into a securities purchase agreement with institutional investors. The deal involves the sale of approximately 1.36 million shares of its common stock, alongside Series A and Series B warrants, enabling further financial options for the company. The initial upfront gross proceeds are expected to be about $4.5 million, with an additional potential of $12 million contingent on the full exercise of the Series Warrants.

The Series A warrants will be valid for a period of 5.5 years, while the short-term Series B warrants have a two-year expiration. This offering is anticipated to close around June 12, 2026, pending the fulfillment of typical closing conditions.

Rodman & Renshaw LLC is acting as the exclusive placement agent, ensuring a smooth transaction process for Atossa. The funds from this offering are intended to support the clinical development of the company’s innovative product candidates, as well as assist with general operational costs.

Atossa is actively engaged in the development of pioneering therapies aimed at addressing significant unmet medical needs within the field of oncology. One of its lead candidates, (Z)-endoxifen, is currently in various stages of clinical trials, showcasing promising potential in treating breast cancer and other malignancies.

This latest funding initiative underscores Atossa's commitment to advancing its oncology programs and accelerating research that can replace outdated therapies with cutting-edge solutions. The company continues to prioritize innovation and efficacy in its drug development pipelines, aiming to improve patient outcomes significantly.

As with all forward-looking statements, Atossa emphasizes that several uncertainties may influence the achievement of its goals. Market dynamics, clinical trial results, regulatory approvals, and other variables could affect the company’s trajectory.

For more information on Atossa's offerings and recent developments, interested parties can visit their official website at https://atossatherapeutics.com.